// App-Quantinova.ai

: COST COMPARISON OF HIGHLY PURIFIED HUMAN MENOPAUSAL GONADOTROPIN (HP-HMG) VERSUS RECOMBINANT FOLLICLE-STIMULATING HORMONE (RFSH) FOR CONTROLLED OVARIAN STIMULATION IN US HIGH-RESPONDER PATIENTS BASED ON THE MEGASET-HR TRIAL

Researchers

Presenter

  • Andrew F. Khair

Principal Investigators

  • Tray Brown

  • Marie Markert

  • Carl H. Samuelsen

  • Carsten Barse

  • Gaurang S. Daftary

  • Patrick W. Heiser

Medical Centers

  • Ferring Pharmaceuticals, Inc., Parsippany, NJ

  • (HEOR) Ltd, Health Economics and Outcomes Research, Cardiff, United Kingdom

  • Ferring Pharmaceuticals, Copenhagen, Denmark

  • Outcomes Analytica AS, Oslo, Norway

Locations

  • United States

  • United Kingdom

  • Denmark

  • Norway

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

Disease

  • Ovarian hyperstimulation syndrome

Biomarkers

  • Anti-Müllerian hormone

  • Body mass index

Drug/Treatment

  • Menotropin

Outcome

  • N/A

Study Design

  • Randomized

  • Non Inferiority

  • Controlled

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved